Peripheral T-cell lymphomas are a diverse group of lymphoproliferative disorders with differing clinical presentations and biological behavior. The optimal treatment of these diseases is determined by an accurate diagnosis as well as determination of the unique phenotype, genetics and prognostic factors of each disease entity. While combination chemotherapy is the backbone of treatment for these patients, many patients may benefit from additional therapy such as brentuximab vedotin, radiation therapy, or stem cell transplantation.
Keywords: Frontline; NA; PTCL.